NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved a new stock buy-back program that authorizes the firm to repurchase up to $75 million of its outstanding common stock.

Illumina said that it has terminated a previously announced $120 million repurchase program after repurchasing $70.7 million of outstanding common stock in 2008.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.